thalidomide has been researched along with betamethasone-17,21-dipropionate in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 6 (85.71) | 2.80 |
| Authors | Studies |
|---|---|
| Bewley, AP; Calzavara-Pinton, PG; Hansen, JB; Nyeland, ME; Shear, NH; Signorovitch, J | 1 |
| Akiyama, M; Ando, Y; Ohshima, Y; Takama, H; Watanabe, D; Yanagishita, T | 1 |
| Alonso-Llamazares, J; Cantrell, W; Kircik, L; Koo, J; Moore, A; Stein Gold, L; Teng, J | 1 |
| Kircik, LH; Schlesinger, TE; Tanghetti, E | 1 |
| Bagel, J; Hetzel, A; Nelson, E; Riley, C | 1 |
| Hegde, AR; Jagadish, PC; Jain, S; Kini, SG; Mullick, P; Mutalik, S; Mutalik, SP; Pandey, A | 1 |
| Kircik, L; Ozyurekoglu, E | 1 |
1 review(s) available for thalidomide and betamethasone-17,21-dipropionate
| Article | Year |
|---|---|
Fixed Combination Calcipotriene and Betamethasone Dipropionate (Cal/BD) Foam for Beyond-Mild Psoriasis: A Possible Alternative to Systemic Medication.
Topics: Administration, Cutaneous; Aerosols; Betamethasone; Biological Products; Calcitriol; Cost-Benefit Analysis; Dermatologic Agents; Drug Combinations; Drug Therapy, Combination; Humans; Psoriasis; Randomized Controlled Trials as Topic; Severity of Illness Index; Thalidomide; Treatment Outcome | 2020 |
2 trial(s) available for thalidomide and betamethasone-17,21-dipropionate
| Article | Year |
|---|---|
Efficacy and Safety of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam With Apremilast for Moderate Plaque Psoriasis.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aerosols; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pruritus; Psoriasis; Quality of Life; Severity of Illness Index; Thalidomide; Treatment Outcome; Visual Analog Scale | 2020 |
Apremilast with Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis.
Topics: Administration, Cutaneous; Adult; Aerosols; Aged; Betamethasone; Calcitriol; Diarrhea; Drug Combinations; Drug Therapy, Combination; Female; Headache; Humans; Male; Middle Aged; Nausea; Pilot Projects; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome; Young Adult | 2020 |
4 other study(ies) available for thalidomide and betamethasone-17,21-dipropionate
| Article | Year |
|---|---|
Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison.
Topics: Acitretin; Administration, Cutaneous; Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Esters; Female; Fumarates; Humans; Male; Methotrexate; Middle Aged; Psoriasis; Thalidomide; Treatment Outcome | 2019 |
Two cases of refractory nail psoriasis successfully treated with calcipotriol plus betamethasone dipropionate gel.
Topics: Administration, Oral; Aged; Betamethasone; Calcitriol; Cyclosporine; Dermatologic Agents; Drug Combinations; Drug Resistance; Female; Gels; Humans; Male; Middle Aged; Nail Diseases; Ointments; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2020 |
Simultaneous Estimation of Apremilast and Betamethasone Dipropionate in Microsponge-Based Topical Formulation using a Stability Indicating RP-HPLC Method: A Quality-by-Design Approach.
Topics: Betamethasone; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Thalidomide | 2021 |
The Maintenance Effect of Calcipotriene 0.05% and Betamethasone Dipropionate 0.064% (Cal/BD) Aerosol Foam in Combination With Apremilast.
Topics: Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Pilot Projects; Psoriasis; Thalidomide; Treatment Outcome | 2022 |